Karyopharm Secures Critical $30M Private Placement, Reports Mixed Phase 3 Myelofibrosis Data, Withdraws DLBCL Approval
KPTI has more than doubled off its 52-week low of $3.51.
Summary
Karyopharm secured a $30 million private placement, crucial for addressing its going concern warning, and reported mixed Phase 3 myelofibrosis trial results with a promising overall survival signal, while also withdrawing accelerated approval for its DLBCL indication.
Key Events · Financing and Capital Events · KPTI
-
Secured $30 Million Private Placement
Karyopharm entered into a private placement with RA Capital Management, securing $30 million in gross proceeds by issuing 1,030,354 shares of common stock at $6.785 per share and 3,391,164 pre-funded warrants at $6.7849 per pre-funded warrant, along with 4,421,518 common stock warrants with an exercise price of $10.00 per share. This capital raise is critical for the company, which previously issued a going concern warning.
-
Mixed Phase 3 SENTRY Trial Results in Myelofibrosis
The Phase 3 SENTRY trial for selinexor in myelofibrosis met its first co-primary endpoint (spleen volume reduction of 35% or more) but did not meet the second co-primary endpoint (absolute total symptom score). A promising overall survival signal was observed (HR 0.43, nominal one-sided p=0.0222), and the company plans to discuss the data with the FDA for a potential sNDA filing.
-
Withdrawal of DLBCL Accelerated Approval
The company agreed to voluntarily withdraw the accelerated approval for its Diffuse Large B-Cell Lymphoma (DLBCL) indication of XPOVIO following an FDA request due to the inability to complete a confirmatory trial. Karyopharm stated this indication generates immaterial revenue.
-
ATM Program Activity
In March 2026, Karyopharm sold 1,100,844 shares through its At-The-Market (ATM) program, generating approximately $9.6 million in net proceeds, adding to its liquidity but also contributing to dilution.
Analysis · KPTI · Life Sciences
This filing is critical for Karyopharm Therapeutics, which previously issued a going concern warning. The company secured $30 million in gross proceeds from a private placement, with potential for an additional $44 million from warrant exercises. This capital infusion, though highly dilutive and priced at a discount for initial shares, is essential for the company's survival and satisfies a capital raise condition for its credit and forbearance agreements to become effective. Concurrently, the Phase 3 SENTRY trial for selinexor in myelofibrosis showed mixed results, meeting one co-primary endpoint (spleen volume reduction) but missing another (symptom improvement), while demonstrating a promising overall survival signal. The company plans to discuss these results with the FDA for a potential sNDA filing. Additionally, Karyopharm agreed to withdraw the accelerated approval for its DLBCL indication of XPOVIO, citing immaterial revenue from this indication. The company also raised $9.6 million through its ATM program in March. The combination of a significant, albeit dilutive, capital raise and mixed but potentially viable clinical data for a key asset provides a path forward for the company.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 41.4% of the 440 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KPTI was trading at $8.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $122.2M. The 52-week trading range was $3.51 to $10.99. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.